Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Could Seek New Indication For Iressa In Europe

This article was originally published in The Pink Sheet Daily

Executive Summary

The company announces withdrawal of European Marketing Authorisation Application for gefitinib in treatment of non-small cell lung cancer. FDA is expected to provide an update on the status of Iressa's subpart H approval in January or February.
Advertisement

Related Content

AstraZeneca Gives Iressa Another Go In The EU
AstraZeneca Gives Iressa Another Go In The EU
Iressa Advisory Committee Will Not Vote On Oncologic’s Status – AstraZeneca
Iressa Advisory Committee Will Not Vote On Oncologic’s Status – AstraZeneca
Fate Of AstraZeneca's Iressa To Be Discussed By Advisory Cmte. March 4
Fate Of AstraZeneca's Iressa To Be Discussed By Advisory Cmte. March 4
AstraZeneca Decision On Anticoagulant Strategy Likely In Late ’05
Genentech Builds Tarceva Inventory Following Iressa's Failed Trial
Iressa Promotion Halted; AstraZeneca To Highlight Tarceva Survival Benefit
Iressa Promotion Halted; AstraZeneca To Highlight Tarceva Survival Benefit

Topics

Advertisement
UsernamePublicRestriction

Register

PS061015

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel